Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Additional Information (Details)

v3.22.2
Fair Value Measurements - Additional Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Estimated fair value of equity securities $ 34,008,000   $ 34,008,000   $ 37,181,000
Unrealized gain (loss) on equity securities (3,736,000) $ 4,325,000 (3,173,000) $ (6,364,000)  
Vaxcyte, Inc. | Vaxcyte Common Stock          
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Estimated fair value of equity securities 34,000,000.0   34,000,000.0   $ 37,200,000
Unrealized gain (loss) on equity securities $ (3,700,000) $ 4,300,000 $ (3,200,000) $ (6,400,000)  
Equity Securities | Vaxcyte, Inc. | Vaxcyte Common Stock          
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Number of shares held 1,562,879   1,562,879   1,562,879
Fair Value Measurements Recurring          
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Securities held $ 216,686,000   $ 216,686,000   $ 265,750,000
Fair Value Measurements Recurring | Level 3          
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Securities held $ 0   $ 0   $ 0